The document describes a method for inferring cancer subnetwork markers using density-constrained biclustering. It begins with an introduction on personalized medicine and biomarker discovery. The methods section explains that the approach finds densely connected subnetworks that are partially differentially expressed. Experimental results on colon and breast cancer gene expression data show that the method achieves high classification performance. The top inferred subnetwork markers are enriched for processes involved in DNA replication, damage repair, and tumor suppression. Future work is proposed to compare signatures across cancers and integrate additional interaction data.
Dancey Clinical Trials Vancouver Dancey 20110302 Final.Ppt [Compatibility Mode]Warren Hamilton
High content clinical trials involve dense sample collection and complex analyses from small patient numbers. They are important for early drug development and evaluation, addressing biological questions about target and pathway inhibition. Successful high content trials require standardized assays and infrastructure across sites, as well as collaboration between multiple institutions. Challenges include developing new science and technologies, building collaborative partnerships, and establishing operational and informatics systems for specimen and data management.
Dr 70 Poster Presentation Asco Jan 2012 42x56 Print X100 2afsanehmotamed
A study evaluated using the blood biomarkers DR-70 and CEA in combination for colorectal cancer screening. Serum samples from 351 healthy controls and 311 CRC patients were tested for DR-70 and CEA levels. The sensitivity of DR-70 and CEA combined was 58.2%, significantly higher than CEA alone at 37.6%. Sensitivity was highest for early stages I and II at 48% and 47%. Combining the biomarkers showed potential for an effective CRC screening test with improved early detection over current methods.
Multi-scale network biology model & the model librarylaserxiong
This document discusses multi-scale network biology models and a network model library. It describes how the library would contain different types of nodes and edges to represent diverse biological interactions. The library would annotate pre-defined network models and integrate updated models. It also discusses multi-scale networks from the inter-cellular to inter-tissue levels. A case study on prioritizing pre-clinical drugs via prognosis-guided genetic interaction networks is mentioned. The document notes challenges in current disease models for drug development and proposes approaches like synergistic outcome determination and module-module cooperation networks to address them.
The researchers isolated and characterized the temperate mycobacteriophage Butters, which has one of the smallest known mycobacteriophage genomes at 41,491 bp. Using a technique called BRED, they deleted genes in the Butters genome, including the integrase gene gp37 and several orpham genes of unknown function. Deletion of the integrase gene resulted in mutant phages that formed larger, clearer plaques, suggesting a shift to a lytic life cycle. Deletion of the orpham genes gp30 and gp57 resulted in larger plaque sizes but did not prevent lysogeny, indicating these genes are not essential for the lysogenic cycle. Ongoing work includes further characterizing
1) A highly infectious Asian male with pulmonary TB and cavitary lung lesions presented to a NJ public health clinic along with his 8 month old child who also had lung infiltrates.
2) Contact investigation revealed the man lived with his wife and child. His initial TB specimen was sent to a lab in Virginia but results were only reported to the submitting physician.
3) When the NJ TB program learned the man was a NJ resident, they requested his isolate from the Virginia lab for genotyping and molecular drug susceptibility testing (DST).
Stephen Friend NIH PPP Coordinating Committee Meeting 2012-02-16Sage Base
The document discusses using networked team approaches and integrating omics data to build better disease maps through public-private partnerships like CTCAP and Arch2POCM. It proposes sharing clinical and genomic data from comparator arms of trials to create models and de-risking novel drug targets through developing test compounds in a precompetitive space to accelerate new therapies.
The document discusses quality control, filtering, and normalization procedures for Illumina 450k methylation array data. It describes initial quality control checks to identify failed samples and technical artifacts, such as color biases. A variety of normalization approaches are presented, including within-array normalization to correct for color bias and background noise, between-array normalization to remove technical variation across arrays, and data-driven approaches to evaluate different preprocessing methods. The goal of preprocessing is to improve concordance with independent validation data while retaining meaningful biological variation.
This research article describes a novel method using high-density peptide microarrays and computational analysis to identify B-cell epitopes in patients with celiac disease. Overlapping peptide sequences from native and deamidated gliadin proteins were synthesized onto silicon wafers. Serum samples from celiac patients and controls were tested on the microarrays. Computational analysis identified distinct epitope sets that differentiated celiac patients from controls with high accuracy. The identified epitopes have potential for developing improved diagnostic tests for celiac disease.
Dancey Clinical Trials Vancouver Dancey 20110302 Final.Ppt [Compatibility Mode]Warren Hamilton
High content clinical trials involve dense sample collection and complex analyses from small patient numbers. They are important for early drug development and evaluation, addressing biological questions about target and pathway inhibition. Successful high content trials require standardized assays and infrastructure across sites, as well as collaboration between multiple institutions. Challenges include developing new science and technologies, building collaborative partnerships, and establishing operational and informatics systems for specimen and data management.
Dr 70 Poster Presentation Asco Jan 2012 42x56 Print X100 2afsanehmotamed
A study evaluated using the blood biomarkers DR-70 and CEA in combination for colorectal cancer screening. Serum samples from 351 healthy controls and 311 CRC patients were tested for DR-70 and CEA levels. The sensitivity of DR-70 and CEA combined was 58.2%, significantly higher than CEA alone at 37.6%. Sensitivity was highest for early stages I and II at 48% and 47%. Combining the biomarkers showed potential for an effective CRC screening test with improved early detection over current methods.
Multi-scale network biology model & the model librarylaserxiong
This document discusses multi-scale network biology models and a network model library. It describes how the library would contain different types of nodes and edges to represent diverse biological interactions. The library would annotate pre-defined network models and integrate updated models. It also discusses multi-scale networks from the inter-cellular to inter-tissue levels. A case study on prioritizing pre-clinical drugs via prognosis-guided genetic interaction networks is mentioned. The document notes challenges in current disease models for drug development and proposes approaches like synergistic outcome determination and module-module cooperation networks to address them.
The researchers isolated and characterized the temperate mycobacteriophage Butters, which has one of the smallest known mycobacteriophage genomes at 41,491 bp. Using a technique called BRED, they deleted genes in the Butters genome, including the integrase gene gp37 and several orpham genes of unknown function. Deletion of the integrase gene resulted in mutant phages that formed larger, clearer plaques, suggesting a shift to a lytic life cycle. Deletion of the orpham genes gp30 and gp57 resulted in larger plaque sizes but did not prevent lysogeny, indicating these genes are not essential for the lysogenic cycle. Ongoing work includes further characterizing
1) A highly infectious Asian male with pulmonary TB and cavitary lung lesions presented to a NJ public health clinic along with his 8 month old child who also had lung infiltrates.
2) Contact investigation revealed the man lived with his wife and child. His initial TB specimen was sent to a lab in Virginia but results were only reported to the submitting physician.
3) When the NJ TB program learned the man was a NJ resident, they requested his isolate from the Virginia lab for genotyping and molecular drug susceptibility testing (DST).
Stephen Friend NIH PPP Coordinating Committee Meeting 2012-02-16Sage Base
The document discusses using networked team approaches and integrating omics data to build better disease maps through public-private partnerships like CTCAP and Arch2POCM. It proposes sharing clinical and genomic data from comparator arms of trials to create models and de-risking novel drug targets through developing test compounds in a precompetitive space to accelerate new therapies.
The document discusses quality control, filtering, and normalization procedures for Illumina 450k methylation array data. It describes initial quality control checks to identify failed samples and technical artifacts, such as color biases. A variety of normalization approaches are presented, including within-array normalization to correct for color bias and background noise, between-array normalization to remove technical variation across arrays, and data-driven approaches to evaluate different preprocessing methods. The goal of preprocessing is to improve concordance with independent validation data while retaining meaningful biological variation.
This research article describes a novel method using high-density peptide microarrays and computational analysis to identify B-cell epitopes in patients with celiac disease. Overlapping peptide sequences from native and deamidated gliadin proteins were synthesized onto silicon wafers. Serum samples from celiac patients and controls were tested on the microarrays. Computational analysis identified distinct epitope sets that differentiated celiac patients from controls with high accuracy. The identified epitopes have potential for developing improved diagnostic tests for celiac disease.
Whole exome sequencing is a technique that sequences the coding regions (exons) of the genome to identify genetic variants associated with diseases. It involves extracting DNA from samples, enriching the exome regions, sequencing the exome, and analyzing the data to identify variants linked to specific conditions. While more comprehensive than candidate gene analysis, exome sequencing is still limited compared to whole genome sequencing as it only covers the 2% of the genome that is protein-coding. However, it provides high coverage at a lower cost than whole genome sequencing.
GENETIC BASIS OF PSYCHIATRIC DISRODERS AND THE RELEVANCE OF CLINICAL PRACTICEPRASHNATH javali
Presentation regarding the counseling of genetic disorders and the steps involved along with the process of Genetic counseling guidance,way to disclose the results,steps to be taken for the care of mentally ill persons.
This document discusses the potential of metagenomics in drug discovery by unveiling microbial genomes for novel compounds. Metagenomics allows for the extraction and cloning of metagenomic DNA from environmental samples in a culture-independent manner. This reveals unprecedented microbial diversity and encoded functional diversity, including novel genes. Metagenomic methods can uncover these novel genes either through sequence-based or functional screening approaches. The human gut microbiome shows particular promise for biotherapeutic discovery using metagenomics. Novel genes discovered through metagenomics may help create bioengineered probiotics.
There are two main types of genetic association studies: pedigree-based methods and pedigree-independent methods. Pedigree-based methods include positional cloning and the founder gene approach which use linkage analysis and genetic mapping of families. Pedigree-independent methods include the candidate gene approach and genome-wide association studies which examine associations between genetic variants and phenotypes across many individuals.
Exome sequencing for disease gene identification and patient diagnostics, Gen...Copenhagenomics
This document discusses strategies for using exome sequencing in diagnosing genetically heterogeneous diseases with low diagnostic yields from current tests. It presents results from sequencing 50 samples from 5 disorders. The strategies aim to increase diagnostic yield while preventing incidental findings through quality control, automated annotation and prioritization of disease-relevant genes, and a graphical interface. Preliminary results found diagnostic yields varying by disorder but considerably higher than current tests, with over 40% positive reports for one gene package for blindness. The approaches minimize risk of incidental findings and allow standardized, controlled interpretation.
This document discusses the process of new drug discovery, including target identification, validation strategies like transgenic animals and antisense technology, hit discovery through physiological and high-throughput screening, lead optimization of absorption, distribution, metabolism, and excretion, prediction of drug safety using in vitro, in vivo, and ex vivo methods, estimation of starting doses for clinical trials, and the phases of clinical trials. The conclusion emphasizes that the ultimate test is how the drug performs and that developing a drug requires strategic decisions across many disciplines.
This document summarizes a seminar on genomics presented by Komal Rajgire. It defines genomics as the study of all genes in an organism, including their mapping, sequencing, and functional analysis. The key differences between genetics and genomics are outlined. The document discusses approaches in functional genomics like homology searching and expression analysis. It also covers related fields like structural genomics, epigenomics, metagenomics, pharmacogenomics, and the applications and future impact of genomics on medicine, drug discovery, and personalized treatment.
Dr. M. N. Astagimath's presentation discusses genomics, proteomics, and metabolomics. The objectives are to understand the concepts and define each term. Genomics is the study of genomes and involves functional, structural, and epigenomics. Proteomics is the large-scale study of proteins and involves expression, interaction, and biomarker analysis. Metabolomics is the study of small molecule metabolites and their profiles can provide unique fingerprints of cellular processes. A variety of methods are used in each field like sequencing and mass spectrometry. The data has applications in medicine such as diagnosis, risk assessment, and bioengineering.
Genomic selection is a form of marker-assisted selection that uses genetic markers covering the entire genome to calculate breeding values and predict an individual's performance. It has several potential advantages over traditional phenotypic and marker-assisted selection, including higher selection accuracy, shorter breeding cycles, and the ability to select individuals earlier. While genomic selection has been widely adopted in animal breeding, its application in plant breeding is still developing, with many studies focusing on crops like maize. Further improvements in statistical models, genotyping technologies, and databases will help increase prediction accuracy and support wider use of genomic selection in plant breeding programs.
Functional genomics,Pharmaco genomics, and Meta genomics.sangeeta jadav
Functional genomics, pharmacogenomics, and metagenomics are methods for determining the roles of genes. Functional genomics examines gene function through techniques like gene knockouts, microarrays, and RNA sequencing. Pharmacogenomics studies how genes affect individual responses to drugs in terms of metabolism and efficacy. Metagenomics analyzes the collective genomes of microbial communities through direct environmental DNA sequencing without requiring isolation of individual species.
Course: Bioinformatics for Biomedical Research (2014).
Session: 3.2- Basic Aspects of Microarray Technology and Data Analysis.
Statistics and Bioinformatisc Unit (UEB) & High Technology Unit (UAT) from Vall d'Hebron Research Institute (www.vhir.org), Barcelona.
Advances and Applications Enabled by Single Cell TechnologyQIAGEN
Over the past 5 years, single-cell genomics have become a powerful technology for studying small samples and rare cells, and for dissecting complex populations such as heterogeneous tumors. Single-cell technology is enabling many new insights into diverse research areas from oncology, immunology and microbiology to neuroscience, stem cell and developmental biology. This webinar introduces single-cell technology and summarizes the newest scientific applications in various research areas, all in the context of current literature.
Microarrays allow researchers to study gene expression across thousands of genes at once. They work by immobilizing DNA probes on a solid surface, then exposing the surface to fluorescently labeled cDNA or cRNA from samples. The microarray is then scanned to see which probes fluoresce, indicating gene expression. Microarrays have many applications including disease diagnosis, drug discovery, and toxicology. While powerful, they also have limitations like expense and complexity of data analysis. Standards are being developed to allow use of microarray data in regulatory decision making.
DNA fingerprint methods. • The locations for genes for specific traits such as egg number, body weight or carcass quality can be identified using markers and then they can be selected directly.
DNA barcoding can be useful for authenticating raw botanical materials but has significant limitations for finished botanical dietary supplements due to degradation of DNA during extraction. The New York Attorney General's investigation into supplement products inappropriately used DNA barcoding on extracts and may have lacked sufficient knowledge of testing complex botanical products. Without details on methodology, reference sequences, and quality controls, the conclusions that many products lacked labeled ingredients cannot be validated. DNA testing must be performed appropriately according to limitations of materials and methods to produce reliable results.
The document summarizes a session on designing drugs for central nervous system target classes. The session will include talks on:
1. Targeting protein-protein interactions, which is becoming more feasible as a drug strategy.
2. Challenges in targeting kinases for neurodegenerative diseases.
3. Considerations for druggability of G protein-coupled receptors and ion channels.
4. Unique challenges and lessons learned from developing biologics for difficult targets.
NGS in Clinical Research: Meet the NGS Experts Series Part 1QIAGEN
Next generation sequencing has revolutionized clinical testing but has also created novel challenges. This presentation will give an overview of state of the art clinical NGS and discuss validation, clinical implementation as well as the migration from gene panels to exome sequencing for inherited disorders with clinical and genetic heterogeneity. In addition, important shortcomings such as difficulties with regions of high sequence homology will be discussed.
The document discusses several types of genomics: structural genomics aims to determine the 3D structure of every protein encoded in a genome. Functional genomics determines the biological functions of genes and their products. Mutational genomics characterizes mutation-associated genes and links genotypes to transcriptional states. Comparative genomics compares genomic features between species to study evolution and identify conserved and unique genes.
Strategies for Effective Upskilling is a presentation by Chinwendu Peace in a Your Skill Boost Masterclass organisation by the Excellence Foundation for South Sudan on 08th and 09th June 2024 from 1 PM to 3 PM on each day.
How to Add Chatter in the odoo 17 ERP ModuleCeline George
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
Whole exome sequencing is a technique that sequences the coding regions (exons) of the genome to identify genetic variants associated with diseases. It involves extracting DNA from samples, enriching the exome regions, sequencing the exome, and analyzing the data to identify variants linked to specific conditions. While more comprehensive than candidate gene analysis, exome sequencing is still limited compared to whole genome sequencing as it only covers the 2% of the genome that is protein-coding. However, it provides high coverage at a lower cost than whole genome sequencing.
GENETIC BASIS OF PSYCHIATRIC DISRODERS AND THE RELEVANCE OF CLINICAL PRACTICEPRASHNATH javali
Presentation regarding the counseling of genetic disorders and the steps involved along with the process of Genetic counseling guidance,way to disclose the results,steps to be taken for the care of mentally ill persons.
This document discusses the potential of metagenomics in drug discovery by unveiling microbial genomes for novel compounds. Metagenomics allows for the extraction and cloning of metagenomic DNA from environmental samples in a culture-independent manner. This reveals unprecedented microbial diversity and encoded functional diversity, including novel genes. Metagenomic methods can uncover these novel genes either through sequence-based or functional screening approaches. The human gut microbiome shows particular promise for biotherapeutic discovery using metagenomics. Novel genes discovered through metagenomics may help create bioengineered probiotics.
There are two main types of genetic association studies: pedigree-based methods and pedigree-independent methods. Pedigree-based methods include positional cloning and the founder gene approach which use linkage analysis and genetic mapping of families. Pedigree-independent methods include the candidate gene approach and genome-wide association studies which examine associations between genetic variants and phenotypes across many individuals.
Exome sequencing for disease gene identification and patient diagnostics, Gen...Copenhagenomics
This document discusses strategies for using exome sequencing in diagnosing genetically heterogeneous diseases with low diagnostic yields from current tests. It presents results from sequencing 50 samples from 5 disorders. The strategies aim to increase diagnostic yield while preventing incidental findings through quality control, automated annotation and prioritization of disease-relevant genes, and a graphical interface. Preliminary results found diagnostic yields varying by disorder but considerably higher than current tests, with over 40% positive reports for one gene package for blindness. The approaches minimize risk of incidental findings and allow standardized, controlled interpretation.
This document discusses the process of new drug discovery, including target identification, validation strategies like transgenic animals and antisense technology, hit discovery through physiological and high-throughput screening, lead optimization of absorption, distribution, metabolism, and excretion, prediction of drug safety using in vitro, in vivo, and ex vivo methods, estimation of starting doses for clinical trials, and the phases of clinical trials. The conclusion emphasizes that the ultimate test is how the drug performs and that developing a drug requires strategic decisions across many disciplines.
This document summarizes a seminar on genomics presented by Komal Rajgire. It defines genomics as the study of all genes in an organism, including their mapping, sequencing, and functional analysis. The key differences between genetics and genomics are outlined. The document discusses approaches in functional genomics like homology searching and expression analysis. It also covers related fields like structural genomics, epigenomics, metagenomics, pharmacogenomics, and the applications and future impact of genomics on medicine, drug discovery, and personalized treatment.
Dr. M. N. Astagimath's presentation discusses genomics, proteomics, and metabolomics. The objectives are to understand the concepts and define each term. Genomics is the study of genomes and involves functional, structural, and epigenomics. Proteomics is the large-scale study of proteins and involves expression, interaction, and biomarker analysis. Metabolomics is the study of small molecule metabolites and their profiles can provide unique fingerprints of cellular processes. A variety of methods are used in each field like sequencing and mass spectrometry. The data has applications in medicine such as diagnosis, risk assessment, and bioengineering.
Genomic selection is a form of marker-assisted selection that uses genetic markers covering the entire genome to calculate breeding values and predict an individual's performance. It has several potential advantages over traditional phenotypic and marker-assisted selection, including higher selection accuracy, shorter breeding cycles, and the ability to select individuals earlier. While genomic selection has been widely adopted in animal breeding, its application in plant breeding is still developing, with many studies focusing on crops like maize. Further improvements in statistical models, genotyping technologies, and databases will help increase prediction accuracy and support wider use of genomic selection in plant breeding programs.
Functional genomics,Pharmaco genomics, and Meta genomics.sangeeta jadav
Functional genomics, pharmacogenomics, and metagenomics are methods for determining the roles of genes. Functional genomics examines gene function through techniques like gene knockouts, microarrays, and RNA sequencing. Pharmacogenomics studies how genes affect individual responses to drugs in terms of metabolism and efficacy. Metagenomics analyzes the collective genomes of microbial communities through direct environmental DNA sequencing without requiring isolation of individual species.
Course: Bioinformatics for Biomedical Research (2014).
Session: 3.2- Basic Aspects of Microarray Technology and Data Analysis.
Statistics and Bioinformatisc Unit (UEB) & High Technology Unit (UAT) from Vall d'Hebron Research Institute (www.vhir.org), Barcelona.
Advances and Applications Enabled by Single Cell TechnologyQIAGEN
Over the past 5 years, single-cell genomics have become a powerful technology for studying small samples and rare cells, and for dissecting complex populations such as heterogeneous tumors. Single-cell technology is enabling many new insights into diverse research areas from oncology, immunology and microbiology to neuroscience, stem cell and developmental biology. This webinar introduces single-cell technology and summarizes the newest scientific applications in various research areas, all in the context of current literature.
Microarrays allow researchers to study gene expression across thousands of genes at once. They work by immobilizing DNA probes on a solid surface, then exposing the surface to fluorescently labeled cDNA or cRNA from samples. The microarray is then scanned to see which probes fluoresce, indicating gene expression. Microarrays have many applications including disease diagnosis, drug discovery, and toxicology. While powerful, they also have limitations like expense and complexity of data analysis. Standards are being developed to allow use of microarray data in regulatory decision making.
DNA fingerprint methods. • The locations for genes for specific traits such as egg number, body weight or carcass quality can be identified using markers and then they can be selected directly.
DNA barcoding can be useful for authenticating raw botanical materials but has significant limitations for finished botanical dietary supplements due to degradation of DNA during extraction. The New York Attorney General's investigation into supplement products inappropriately used DNA barcoding on extracts and may have lacked sufficient knowledge of testing complex botanical products. Without details on methodology, reference sequences, and quality controls, the conclusions that many products lacked labeled ingredients cannot be validated. DNA testing must be performed appropriately according to limitations of materials and methods to produce reliable results.
The document summarizes a session on designing drugs for central nervous system target classes. The session will include talks on:
1. Targeting protein-protein interactions, which is becoming more feasible as a drug strategy.
2. Challenges in targeting kinases for neurodegenerative diseases.
3. Considerations for druggability of G protein-coupled receptors and ion channels.
4. Unique challenges and lessons learned from developing biologics for difficult targets.
NGS in Clinical Research: Meet the NGS Experts Series Part 1QIAGEN
Next generation sequencing has revolutionized clinical testing but has also created novel challenges. This presentation will give an overview of state of the art clinical NGS and discuss validation, clinical implementation as well as the migration from gene panels to exome sequencing for inherited disorders with clinical and genetic heterogeneity. In addition, important shortcomings such as difficulties with regions of high sequence homology will be discussed.
The document discusses several types of genomics: structural genomics aims to determine the 3D structure of every protein encoded in a genome. Functional genomics determines the biological functions of genes and their products. Mutational genomics characterizes mutation-associated genes and links genotypes to transcriptional states. Comparative genomics compares genomic features between species to study evolution and identify conserved and unique genes.
Strategies for Effective Upskilling is a presentation by Chinwendu Peace in a Your Skill Boost Masterclass organisation by the Excellence Foundation for South Sudan on 08th and 09th June 2024 from 1 PM to 3 PM on each day.
How to Add Chatter in the odoo 17 ERP ModuleCeline George
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
How to Manage Your Lost Opportunities in Odoo 17 CRMCeline George
Odoo 17 CRM allows us to track why we lose sales opportunities with "Lost Reasons." This helps analyze our sales process and identify areas for improvement. Here's how to configure lost reasons in Odoo 17 CRM
This presentation was provided by Steph Pollock of The American Psychological Association’s Journals Program, and Damita Snow, of The American Society of Civil Engineers (ASCE), for the initial session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session One: 'Setting Expectations: a DEIA Primer,' was held June 6, 2024.
The simplified electron and muon model, Oscillating Spacetime: The Foundation...RitikBhardwaj56
Discover the Simplified Electron and Muon Model: A New Wave-Based Approach to Understanding Particles delves into a groundbreaking theory that presents electrons and muons as rotating soliton waves within oscillating spacetime. Geared towards students, researchers, and science buffs, this book breaks down complex ideas into simple explanations. It covers topics such as electron waves, temporal dynamics, and the implications of this model on particle physics. With clear illustrations and easy-to-follow explanations, readers will gain a new outlook on the universe's fundamental nature.
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
How to Fix the Import Error in the Odoo 17Celine George
An import error occurs when a program fails to import a module or library, disrupting its execution. In languages like Python, this issue arises when the specified module cannot be found or accessed, hindering the program's functionality. Resolving import errors is crucial for maintaining smooth software operation and uninterrupted development processes.
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar Kanvaria
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
How to Make a Field Mandatory in Odoo 17Celine George
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
1. Guideline Introduction Methods Experimental Results
Inferring Cancer Subnetwork Markers
using Density-Constrained Biclustering
Presenters: Phuong Dao1 , Alexander Schonhuth2
1
School of Computing Science, Simon Fraser University
2
Algorithmic Computational Biology Group, CWI, Netherlands
3. Guideline Introduction Methods Experimental Results
Introduction
Personalized Medicine
• Exact determination of disease status based on
patient genetics/genomics
• Goal: Specific, individual choice of treatment
4. Guideline Introduction Methods Experimental Results
Introduction
Personalized Medicine
• Exact determination of disease status based on
patient genetics/genomics
• Goal: Specific, individual choice of treatment
• Necessary: Reliable disease markers
5. Guideline Introduction Methods Experimental Results
Biomarker Discovery
• Single gene markers: Each gene is ranked according to
their ability to distinguish samples of different classes
• Multigenic markers: Each subset S of genes is ranked
based on the aggregation ability of all genes in S to
distinguish samples of different classes
6. Guideline Introduction Methods Experimental Results
Single Gene Markers
Control 1
Control 2
Control 3
Case 1
Case 2
Case 3
Control 1
Control 2
Control 3
Case 1
Case 2
Case 3
Gene 1
Gene 3
Gene 1
Gene 2 Differentially Expressed
Gene 3
Gene 4 Gene 2
Gene 5 Gene 4
Gene 6 Gene 5
Gene 6
Non−Differentially Expressed
7. Guideline Introduction Methods Experimental Results
Multigenic Markers
Subnetwork Markers
[Chuang et al., Mol.Sys.Biol. (2007)]:
• Predicting progression of breast
cancer
• Subnetwork markers are
connected subnetworks with
aggregate expression profiles
correlates the most with the labels
of the samples
• Greedy heuristics for searching
for optimal subnetwork markers
8. Guideline Introduction Methods Experimental Results
Multigenic Markers
Subnetwork Markers
[Chowdhury et al., PSB 2010]:
• Predicting colon cancer subtypes
• Each marker is a small connected subnetwork N such that genes
in N cover all disease samples (gene g covers sample s if g is
differentially expressed in s)
• Greedy heuristics for searching for the smallest subnetwork
markers
9. Guideline Introduction Methods Experimental Results
Motivations
Heterogeneity of Cancer Genomes
• Cancer genomes evolve
(many cells in one
patient have different
genomes)
• No two cancer cells of
two different patients
are the same
[Hampton et al., Genome Research (2009)]
10. Guideline Introduction Methods Experimental Results
Motivations
Proximity of Disease Related Genes in PPI Network
[Goh et al., PNAS (2007)]:
• The protein products of genes related to the same disease tend to
interact with one another
• Genes related to a disease have coherent functions with respect to the
Gene Ontology hierarchy
11. Guideline Introduction Methods Experimental Results
Our Approach
Each of our subnetwork markers:
• includes genes that have higher interaction among
them than expected (densely connected
subnetworks)
• contains differentially expressed genes in a fraction of
all the samples from cancer tissues (partially
differential expression)
13. Guideline Introduction Methods Experimental Results
Densely Connected Subnetworks
Properties
Let G = (V , E) be a network with edge weights we , e ∈ E.
• The density θ(G) of G is
e∈E we
θ(G) := |V |
2
|V |
where 2 is the number of possible edges in G.
• G is called α-dense if
θ(G) ≥ α.
• An α-dense, connected network G is called α-densely
connected.
15. Guideline Introduction Methods Experimental Results
Density Constrained Biclustering
Search Strategy
Theorem: Let α ≥ 0.5. Every α-densely connected network of size n
contains an α-densely connected subnetwork of size n − 1.
0.4 A 0.6 A 0.9 A C 0.8 D C
B C D B B D
C
0.6 A 0.6 A 0.9 A 0.8 D
0.4 0.6
B A C 0.4 C 0.9 D 0.4 B
0.9 B D 0.8 B C
0.8
D
Density: 0.45
= [(0.8 + 0.9 + 0.6 + 0.4) / 6] C
Not Dense wDCB
0.4 0.6
B A
0.9
0.8
Not Connected D maximal wDCB
Figure: Toy example for computation of densely connected subnetworks,
density threshold θ = 0.5.
16. Guideline Introduction Methods Experimental Results
Classifier Construction
G4
G1
0.95 0.9
0.85 0.7
0.75 G3 G5
1. Rank density constrained G2 G6
biclusters according to density 0.8
0.9
0.85
significance G4 0.95
G7
2. Keep only high-ranked
Gene 1 1.25
subnetworks with little overlap Gene 2 1.5
3. Feature space dimension = Gene 3 1.0
Marker 1 1.25
Gene 4 1.25 Average
number of markers Gene 5 0.5
Marker 2 0.5
4. SVM classification Gene 6 0.0
Gene 7 0.25
Gene Expression Profile Average Gene Expression Profile
18. Guideline Introduction Methods Experimental Results
Network Data
Confidence-scored PPI network
[STRING, von Mering et al., NAR 2009]
• Edges reflect physical
protein-protein interactions
• Confidence scores reflect the
probability that the interaction is 0.95
0.6 0.8
0.9
associated with a cellular 0.45
0.75
0.85
0.9
0.25 0.9
0.7
phenomenon (and not an 0.8 0.55
0.95
0.5 0.95
0.75
0.85
0.95
experimental artifact) 0.45
0.35 0.65
0.8
0.75 0.8
0.9
0.9 0.7
0.3 0.8
• Scoring system based on KEGG 0.65
0.75 0.8
0.9
0.9
0.85
0.95
pathways
19. Guideline Introduction Methods Experimental Results
Gene Expression Data
Three experiments on colon cancer
• GSE8671, 32 patients / tissue pairs
• GSE10950, 24 patients / tissue pairs
• GSE6988, 123 samples across several cancer subtypes
One experiment on breast cancer
• GSE3494, 251 patients with different mutation status (wildtype vs.
mutant)
23. Guideline Introduction Methods Experimental Results
GSE 3494 - Breast Cancer
24. Guideline Introduction Methods Experimental Results
Subnetwork Marker Statistics
Avg AUC Avg AUC
# ER-50 6988 10950 # ER-50 6988 8671
GMI 806 0.38 0.86 0.95 755 0.34 0.84 0.99
NC 923 0.12 0.87 0.99 N/A N/A 0.86 N/A
wDCB 282 0.76 0.91 1.00 216 0.74 0.91 1.00
8671 Subnetworks 10950 Subnetworks
GMI = Greedy Mutual Information (Chuang et al.)
NC = NetCover (Chowdhury et al.)
wDCB = weighted Density Constrained Biclustering
# = total number of subnetworks computed
ER-50 = enrichment rate of the top-50 markers
25. Guideline Introduction Methods Experimental Results
Top Marker 8671
• DNA replication
initiation
• DNA metabolic
process
• TP53, BRCA1: tumor
suppressor genes
• Minichromosome
maintenance (MCM)
complex
• Protein kinase CDC7
phosphorylates
MCM2
26. Guideline Introduction Methods Experimental Results
Top Marker 10950
• Nukleotide excision
• DNA clamp (PCNA)
loader activity
• Polymorphisms in
WRN ↔ colon cancer
• DNMT1: methyl
transferase, silences
cell growth repressors
27. Guideline Introduction Methods Experimental Results
Future Works
1. Comparison subnetwork signatures of different cancers or subtypes of a
particular cancer
2. Extend the interaction network with for example ncRNA-protein interactions
3. Redesign novel methods to work with real valued continuous phenotype
variables
28. Guideline Introduction Methods Experimental Results
Thanks for the attention!